KEY DETAILS
CMS proposed a rule on Oct 20, 2026 addressing Medicare Part D cost-sharing reductions, provider lists and PBM accountability, with comments due Dec 15, 2026.
EMA updated Victoza's EU product information on October 16, 2026, under its type 2 diabetes indication.
A new preprint, not yet peer reviewed, found semaglutide initiation was associated with higher heart rate during sleep, most during REM sleep, unexplained by weight loss.
A cohort study linked high-dose semaglutide starts to earlier discontinuation and decreased 1-year persistence.
This roundup covers a general Medicare proposed rule, an update to a European product information record, and new research on semaglutide. None of it changes what is approved or available, but it adds details that patients and prescribers may find useful. If you use a GLP-1 drug, or help someone who does, these updates are worth a few minutes of your time.
The Centers for Medicare & Medicaid Services proposed a rule on October 20, 2026, to carry out three sections of the Consolidated Appropriations Act, 2026. The rule covers adjustments to Medicare Part D cost-sharing reductions for low-income individuals, a requirement for more accurate lists of health providers, and new accountability rules for pharmacy benefit managers. The proposal does not mention GLP-1 drugs. It is a proposed rule, not a final one, so nothing is settled yet. Public comments are open through December 15, 2026.
The European Medicines Agency updated Victoza's EU product information on October 16, 2026, under procedure VR/0000362001. Victoza, Novo Nordisk's liraglutide brand, has been authorized in the EU since June 30, 2009, for adults, adolescents, and children aged 10 and older with insufficiently controlled type 2 diabetes who need it alongside diet and exercise. This update only touches the product information tied to that existing authorization. It does not represent a new approval or a new use for the drug.
A new preprint, listed October 20, 2026, and not yet peer reviewed, looked at heart rate patterns after people started semaglutide. The researchers found semaglutide initiation was associated with higher heart rate throughout sleep, most during REM sleep, and this was not explained by weight loss. The authors also noted that clinic measurements may understate the effect. Because this is a preprint, it has not gone through peer review, so the findings have not yet been vetted by outside researchers.
A cohort study published in Diabetes, Obesity and Metabolism on October 19, 2026, looked at real-world patterns of starting injectable semaglutide in the United States. It found that starting at high doses is common in practice, and that high-dose initiation is associated with earlier discontinuation and decreased 1-year persistence. The study describes high-dose initiation as a modifiable risk factor. This is a cohort study, not a randomized trial, so it shows an association rather than a proven cause.
Reading the original documents directly is the best way to see exactly what each one says and does not say. Nothing here tells you what to do, but it does show what regulators and researchers are currently looking at.
Originally published on GLP1Laws.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.